PNL4

**PNL4** is one of five experimental PEGylated nanoliposome formulations evaluated in a peer-reviewed preclinical study of approaches to reduce alpha-synuclein pathology. The formulation was assessed for effects on alpha-synuclein fibrillization, inflammatory activation of BV2 microglia, and SNCA expression. In contrast with PNL1 and PNL2, PNL4 did not demonstrate inhibition of alpha-synuclein aggregation or attenuation of neuroinflammation in the reported experiments. The publication indicates that PNL4 contained omega-3 and/or mannitol-related components, but does not establish PNL4 as a clinically developed therapeutic product or define a validated therapeutic mechanism for this specific formulation.